

CardiacSense Ltd – January 2022 report

1. The watch

- 1.1. In the past month we have started the watches assembly in our facility in Caesarea. The production of watches parts (i.e., PCBs, plastic parts) are still being produced by subcontractors in Israel and China. It is very exciting for us to see the final watches packed in their boxes in our house!
- 1.2. We expect 1,000 watches to be assembled and shipped during February/March.
- 1.3. Watch, mobile and cloud applications are getting more and more stable and additional features are added. The focus in coming months will be enlarging cloud services.

2. IP

We got a formal notice from the European Patent Authority that we will get a patent in Europe in the coming months. This is an important patent that describes our sensors innovation.

3. Clinical trials and Regulatory:

- 3.1. We are continuing our clinical trials in Israel (Ichilov and Rambam) hospitals, but due to the Covid-19 situation rate of the tests are slower.
- 3.2. We are accelerating the Blood Pressure development and hence performing few clinical trials for this indication. In the past month we had additional data collection clinical trial of in the USA. We will have additional BP trial in the US toward the end of this month and another one next month. The data we collect in these trials enable us to improve our BP algorithm. The interim results we see are encouraging.

4. Marketing:

- 4.1. We have signed additional distribution agreement with Czechia and Slovakia. Our current backlog reached 170 million dollars